Consensus on the medical treatment of colon cancer

[1]  W. Scheithauer,et al.  EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Stephens,et al.  Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Greil,et al.  Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. , 2008, Clinical colorectal cancer.

[5]  D. Kerr,et al.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.

[6]  Jeffery T. Sloan,et al.  Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  W. Scheithauer,et al.  1LB 5-year overall survival update from the X-ACT trial of capecitabine vs. 5-FU/LV as adjuvant treatment for stage-III colon cancer , 2007 .

[8]  W. Scheithauer,et al.  3064 POSTER Neoadjuvant bevacizumab plus XELOX is feasible in patients with potentially curable metastatic colorectal cancer receiving synchronous resection , 2007 .

[9]  P. Lebrun,et al.  3001 ORAL CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC) , 2007 .

[10]  C. Bokemeyer,et al.  3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS , 2007 .

[11]  A. Carrato,et al.  Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. , 2007, European journal of cancer.

[12]  R. Goldberg,et al.  Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Tournigand,et al.  Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Gray,et al.  Randomised trials of HIV prevention , 2007, The Lancet.

[15]  Richard J Stephens,et al.  Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial , 2007, The Lancet.

[16]  W. Scheithauer,et al.  Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer , 2007 .

[17]  C. Punt,et al.  Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group (DCCG) phase III study , 2007 .

[18]  C. Tournigand,et al.  A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC) , 2007 .

[19]  C. Fuchs,et al.  Safety and efficacy of first-line irinotecan/fluoropymidine combinations in mCRC patients >65 years compared with those ≤65: The BICC-C study , 2007 .

[20]  D. Tu,et al.  Quality of life in patients with advanced colorectal cancer treated with cetuximab: Results of the NCIC CTG and AGITG CO.17 trial , 2007 .

[21]  A. Norman,et al.  A prospective study of oxaliplatin and capecitabine (CapOx) in metastatic colorectal cancer (MCRC) with baseline stratification according to resectability status , 2007 .

[22]  B. Esterni,et al.  XELOX regimen in elderly patients with metastatic colorectal cancer (MCRC), a FNCLCC French Collaborative Group GERICO 02 phase II study , 2007 .

[23]  W. Scheithauer,et al.  Bevacizumab plus XELOX as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer , 2007 .

[24]  T. Hickish,et al.  Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years , 2007 .

[25]  W. Scheithauer,et al.  Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial , 2007 .

[26]  L. Collette,et al.  Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases , 2007 .

[27]  G. Krol,et al.  Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Morrison,et al.  Pain management in hospitalized cancer patients: a systematic review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  L. Crinò,et al.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Cunningham,et al.  Does shorter duration of chemotherapy worsen survival for elderly patients with colon cancer? , 2007, Nature Clinical Practice Oncology.

[32]  E. Steliarova-Foucher,et al.  Hodgkin's disease incidence and survival in European children and adolescents (1978-1997): report from the Automated Cancer Information System project. , 2006, European journal of cancer.

[33]  M. Ychou,et al.  Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. , 2006, European journal of cancer.

[34]  C. Tournigand,et al.  Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Schilsky,et al.  Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Aapro,et al.  MABEL-A large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Carrato,et al.  Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Kopetz,et al.  Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  L. Mineur,et al.  OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Herrmann,et al.  The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  E. Van Cutsem,et al.  Final safety findings from a randomized phase III trial of capecitabine + oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Neugut,et al.  Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Laura-Mae Baldwin,et al.  Completion of therapy by Medicare patients with stage III colon cancer. , 2006, Journal of the National Cancer Institute.

[44]  T. Pawlik,et al.  Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Bardia,et al.  Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  W. Scheithauer,et al.  Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial , 2006, British Journal of Cancer.

[47]  J. Nortier,et al.  Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  T. Seufferlein,et al.  Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  K. Syrigos,et al.  FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) , 2006, British Journal of Cancer.

[50]  C. Tournigand,et al.  [Adjuvant treatment of colon cancer MOSAIC study's main results]. , 2006, Bulletin du cancer.

[51]  C. Tournigand,et al.  OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  B. Nordlinger,et al.  Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases , 2006, Annals of surgery.

[53]  L. Rubbia‐Brandt,et al.  Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. , 2006, Journal of the American College of Surgeons.

[54]  D. Sargent,et al.  Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  S. Agelaki,et al.  Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI Regimen) as First Line Treatment for Elderly Patients with Metastatic Colorectal Cancer: A Phase II Trial , 2005, Oncology.

[56]  Cheryl Ho,et al.  Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  F. Kabbinavar,et al.  Bevacizumab Combined with Standard Fluoropyrimidine-Based Chemotherapy Regimens to Treat Colorectal Cancer , 2005, Oncology.

[58]  N. Wolmark.  Provocative optimism in the treatment of early stage disease. , 2005, The oncologist.

[59]  Y. Bang,et al.  Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer , 2005, Journal of Korean medical science.

[60]  L. Ellis,et al.  Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  C. Köhne,et al.  Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  C. Bokemeyer,et al.  Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Y. Yoon,et al.  Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  T. Conroy,et al.  Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. , 2005, Clinical colorectal cancer.

[65]  M. Rocchi,et al.  High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  Markus Abt,et al.  Capecitabine as adjuvant treatment for stage III colon cancer. , 2005, The New England journal of medicine.

[67]  S. Gill,et al.  Population-based analysis of patients with advanced colorectal cancer: The impact of age on treatment and outcomes , 2005 .

[68]  R. Labianca,et al.  Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3) , 2005 .

[69]  A. Carrato,et al.  Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRA) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5FU. Final results of a phase II study , 2005 .

[70]  F. Lordick,et al.  A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results , 2005 .

[71]  M. Ychou,et al.  A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802) , 2005 .

[72]  Jae Hyun Kim,et al.  Efficacy of reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer (CRC) , 2005 .

[73]  D. Cunningham,et al.  Final results of a randomized phase III study evaluating the addition of oxaliplatin first line to 5-FU followed by irinotecan at progression in advanced colorectal cancer (LIFE study) , 2005 .

[74]  W. Hawkins,et al.  Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. , 2005, Journal of the American College of Surgeons.

[75]  D. Sargent,et al.  FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  A. Carrato,et al.  Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  R. Stupp,et al.  Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  T. Hickish,et al.  A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[80]  P. Rougier,et al.  Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC) , 2005 .

[81]  C. Ko,et al.  Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. , 2005, Journal of the National Cancer Institute.

[82]  M. Buyse,et al.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[84]  M. Ychou,et al.  Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial , 2004 .

[85]  R. Advani,et al.  A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  D. Kerr,et al.  QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  O. Holmberg,et al.  Intensity modulated radiation therapy (IMRT) may reduce the oesophageal toxicity of hypofractionated accelerated 3-D radiation for non small cell lung carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  C. Daugherty,et al.  Education and gender differences in perception of prognosis among advanced cancer patients (ACP) in hospice. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  E. Van Cutsem,et al.  Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[90]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[91]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[92]  S. Cha,et al.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  D. Sargent,et al.  Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  P. Burger,et al.  Biologic risk stratification of medulloblastoma: the real time is now. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  T. Wiggers,et al.  The influence of age on resection rates and postoperative mortality in 6457 patients with colorectal cancer , 2004, International Journal of Colorectal Disease.

[98]  W. Scheithauer,et al.  Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[99]  Marc Buyse,et al.  Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  M. Aapro,et al.  Adjuvant chemotherapy in the elderly. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[101]  R. Adam,et al.  Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[102]  R. Porschen,et al.  5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[103]  E. Lamont,et al.  Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  C. Punt,et al.  Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study , 2002, The Lancet.

[105]  A. Neugut,et al.  Survival Associated with 5-FluorouracilBased Adjuvant Chemotherapy among Elderly Patients with Node-Positive Colon Cancer , 2002, Annals of Internal Medicine.

[106]  C. Lynch,et al.  Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  A. Grothey.  Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) , 2002 .

[108]  C. Begg,et al.  Age and adjuvant chemotherapy use after surgery for stage III colon cancer. , 2001, Journal of the National Cancer Institute.

[109]  A. Grothey,et al.  Phase III trial of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly oxaliplatin (OXA) plus high dose 24h 5-FU infusion/FA in patients with advanced colorectal cancer (CRC) , 2001 .

[110]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[111]  C. Davis,et al.  Surgery for colorectal cancer in elderly patients: a systematic review , 2000, The Lancet.

[112]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  D. Kerr,et al.  Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[114]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[115]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  F. Lévi,et al.  Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[117]  C. Erlichman.  Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  F. Lévi,et al.  Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. , 1996, Annals of surgery.

[119]  J. P. Pignon,et al.  Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators , 1995, The Lancet.

[120]  C. Tangen,et al.  Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report , 1995, Annals of Internal Medicine.